Literature DB >> 25539624

Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.

Jan Krejci1,2, Petr Hude3,4, Hana Poloczkova3,4, Vita Zampachova4,5, Radka Stepanova6, Tomas Freiberger7, Eva Nemcova6,7, Lenka Spinarova3,4.   

Abstract

Patients with myocarditis and left ventricular (LV) dysfunction may improve after standard heart failure therapy. This improvement seems to be related to retreat of myocardial inflammation. The aim of the present study was to assess changes in clinical, echocardiographic and some laboratory parameters and to correlate them with changes in the number of inflammatory infiltrating cells in endomyocardial biopsy (EMB) samples during the 6-month follow-up, and to define predictors of LV function improvement among baseline parameters. Forty patients with biopsy-proven myocarditis and impaired LV function (LV ejection fraction-LVEF <40 %) with heart failure symptoms ≤ 6 months were evaluated. Myocarditis was defined as the presence of >14 mononuclear leukocytes/mm(2) and/or >7 T-lymphocytes/mm(2) in the baseline EMB. The EMB, echocardiography and clinical evaluation were repeated after 6 months of standard heart failure therapy. LVEF improved on average from 25 ± 9 to 42 ± 12 % (p < 0.001); LV end-systolic volume and LV end-diastolic volume (LVEDV) decreased from 158 ± 61 to 111 ± 58 ml and from 211 ± 69 to 178 ± 63 ml (both p < 0.001). NYHA class decreased from 2.6 ± 0.5 to 1.6 ± 0.6 (p < 0.001) and NTproBNP from 2892 ± 3227 to 851 ± 1835 µg/ml (p < 0.001). A decrease in the number of infiltrating leukocytes (CD45+/LCA+) from 23 ± 15 to 13 ± 8 cells/mm(2) and in the number of infiltrating T lymphocytes (CD3+) from 7 ± 5 to 4 ± 3 cells/mm(2) (both p < 0.001) was observed. The decline in the number of infiltrating CD45+ cells significantly correlated with the change in LVEF (R = -0.43; p = 0.006), LVEDV (R = 0.39; p = 0.012), NYHA classification (R = 0.35; p = 0.025), and NTproBNP (R = 0.33; p = 0.045). The decrease in the number of CD3+ cells correlated with the change of systolic and diastolic diameters of the left ventricle (R = -0.33; p = 0.038 and R = -0.45; p = 0.003) and with the change in LVEDV (R = -0.43; p = 0.006). Tricuspid annular plane systolic excursion (TAPSE) (OR 0.61; p = 0.005) and early transmitral diastolic flow velocity (E wave) (OR 0.89; p = 0.002) were identified as predictors of LVEF improvement. Improvements in clinical status, LV function and NTproBNP levels correlated with decrease in the number of infiltrating inflammatory cells. TAPSE and E wave velocity were significant predictors of improvement in multivariate regression. Our observations suggest that contemporary guidelines-based therapy of heart failure is an effective treatment option in patients with recent onset biopsy-proven inflammatory cardiomyopathy.

Entities:  

Keywords:  Echocardiography; Endomyocardial biopsy; Inflammatory cardiomyopathy; Left ventricular dysfunction; Myocarditis

Mesh:

Substances:

Year:  2014        PMID: 25539624     DOI: 10.1007/s00380-014-0618-0

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  50 in total

1.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.

Authors:  R Wojnicz; E Nowalany-Kozielska; C Wojciechowska; G Glanowska; P Wilczewski; T Niklewski; M Zembala; L Polonski; M M Rozek; J Wodniecki
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

2.  Prognostic importance of right ventricular dysfunction.

Authors:  R A Bleasdale; M P Frenneaux
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

3.  Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.

Authors:  Heiko Mahrholdt; Anja Wagner; Claudia C Deluigi; Eva Kispert; Stefan Hager; Gabriel Meinhardt; Holger Vogelsberg; Peter Fritz; Juergen Dippon; C-Thomas Bock; Karin Klingel; Reinhard Kandolf; Udo Sechtem
Journal:  Circulation       Date:  2006-10-02       Impact factor: 29.690

4.  Long-term follow-up on cardiac function following fulminant myocarditis requiring percutaneous extracorporeal cardiopulmonary support.

Authors:  Kohki Ishida; Hiroshi Wada; Kenichi Sakakura; Norifumi Kubo; Nahoko Ikeda; Yoshitaka Sugawara; Junya Ako; Shin-ichi Momomura
Journal:  Heart Vessels       Date:  2011-12-28       Impact factor: 2.037

5.  Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response.

Authors:  Matthias Pauschinger; Susanne Rutschow; Kumaran Chandrasekharan; Dirk Westermann; Anneke Weitz; Lothar Peter Schwimmbeck; Heinz Zeichhardt; Wolfgang Poller; Michel Noutsias; Jun Li; Heinz-Peter Schultheiss; Carsten Tschope
Journal:  Eur J Heart Fail       Date:  2005-06       Impact factor: 15.534

6.  Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy.

Authors:  D M McNamara; R Holubkov; R C Starling; G W Dec; E Loh; G Torre-Amione; A Gass; K Janosko; T Tokarczyk; P Kessler; D L Mann; A M Feldman
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

Review 7.  Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance.

Authors:  Alida L P Caforio; Niall J Mahon; Francesco Tona; William J McKenna
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

8.  Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression.

Authors:  Seiichiro Saegusa; Yu Fei; Takashi Takahashi; Hiroyuki Sumino; Junji Moriya; Ken Kawaura; Jun-ichi Yamakawa; Tohoru Itoh; Shigeto Morimoto; Takeshi Nakahashi; Kunimitsu Iwai; Masayuki Matsumoto; Tsugiyasu Kanda
Journal:  Cardiovasc Drugs Ther       Date:  2007-06       Impact factor: 3.727

9.  Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis.

Authors:  Thomas J Bahk; Melvin D Daniels; Juan S Leon; Kegiang Wang; David M Engman
Journal:  Int J Cardiol       Date:  2007-06-22       Impact factor: 4.164

Review 10.  Acute viral myocarditis.

Authors:  Robert Dennert; Harry J Crijns; Stephane Heymans
Journal:  Eur Heart J       Date:  2008-07-09       Impact factor: 29.983

View more
  6 in total

1.  Shocks after implantable cardioverter-defibrillator implantation in idiopathic cardiomyopathy patients: a myocardial biopsy study.

Authors:  Erdal Safak; Giuseppe D Ancona; Heinz-Peter Schultheiss; Uwe Kühl; Stephan Kische; Hilmi Kaplan; Hüseyin Ince; Jasmin Ortak
Journal:  Heart Vessels       Date:  2017-08-14       Impact factor: 2.037

Review 2.  Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies.

Authors:  Julius L Katzmann; Peter Schlattmann; Angelos G Rigopoulos; Ewa Noutsias; Boris Bigalke; Matthias Pauschinger; Carsten Tschope; Daniel Sedding; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

3.  Delayed-Type Hypersensitivity to Metals of Environmental Burden in Patients with Takotsubo Syndrome - Is There a Clinical Relevance?

Authors:  Jan Manousek; Vera Stejskal; Petr Kubena; Jiri Jarkovsky; Petr Nemec; Petr Lokaj; Ludmila Dostalova; Andrea Zadakova; Marie Pavlusova; Klara Benesova; Petr Kala; Roman Miklik; Jindrich Spinar; Jiri Parenica
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

4.  Clinical predictors of outcome in patients with inflammatory dilated cardiomyopathy.

Authors:  Konstantinos Karatolios; Volker Holzendorf; George Hatzis; Dimitrios Tousoulis; Anette Richter; Bernhard Schieffer; Sabine Pankuweit
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

Review 5.  Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment.

Authors:  Jan Krejci; Dalibor Mlejnek; Dana Sochorova; Petr Nemec
Journal:  Biomed Res Int       Date:  2016-06-12       Impact factor: 3.411

6.  Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy.

Authors:  Dalibor Mlejnek; Jan Krejci; Petr Hude; Eva Ozabalova; Vita Zampachova; Radka Stepanova; Iva Svobodová; Tomas Freiberger; Eva Nemcova; Lenka Spinarova
Journal:  Arch Med Sci       Date:  2018-10-23       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.